462100-06-7

Basic information

• Product Name: 2,2-DIMETHYL-4-OXO-3,8,11,14-TETRAOXA-5-AZAHEXADECAN-16-OIC ACID
• Synonyms: 2,2-DIMETHYL-4-OXO-3,8,11,14-TETRAOXA-5-AZAHEXADECAN-16-OIC ACID;Boc-PEG3- CH2COOH;Boc-11-amino-3,6,9-trioxaundecanoic acid;5,8,11-Trioxa-2-azatridecanedioic acid 1-(1,1-dimethylethyl) ester;Boc-N-amido-PEG3-CH2CO2H;t-boc-N-amido-PEG3-acetic acid;BocNH-PEG3-CH2COOH
• CAS NO: 462100-06-7
• Molecular Formula: C₁₃H₂₅NO₇
• Molecular Weight: 307.3401
• Mol File: 462100-06-7.mol

Chemical Properties

• Boiling Point: 460.1±35.0 °C(Predicted)
• Appearance: /
• Density: 1.141±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C
• PKA: 3.39±0.10(Predicted)
• CAS DataBase Reference: 2,2-DIMETHYL-4-OXO-3,8,11,14-TETRAOXA-5-AZAHEXADECAN-16-OIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-DIMETHYL-4-OXO-3,8,11,14-TETRAOXA-5-AZAHEXADECAN-16-OIC ACID(462100-06-7)
• EPA Substance Registry System: 2,2-DIMETHYL-4-OXO-3,8,11,14-TETRAOXA-5-AZAHEXADECAN-16-OIC ACID(462100-06-7)

Safety Data

• Hazardous Substances Data: 462100-06-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
2,2-DIMETHYL-4-OXO-3,8,11,14-TETRAOXA-5-AZAHEXADECAN-16-OIC ACID is used as a crosslinker in chemical synthesis for its ability to connect molecules through stable amide bonds. The Boc-protected amine allows for selective deprotection, enabling the formation of specific chemical structures.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2,2-DIMETHYL-4-OXO-3,8,11,14-TETRAOXA-5-AZAHEXADECAN-16-OIC ACID is used as a building block for the development of drug candidates. Its unique structure and functional groups can be utilized to create novel therapeutic agents with improved properties, such as enhanced solubility and targeted delivery.
Used in Bioconjugation:
2,2-DIMETHYL-4-OXO-3,8,11,14-TETRAOXA-5-AZAHEXADECAN-16-OIC ACID is used as a bioconjugation agent to attach biologically active molecules, such as peptides, proteins, or nucleic acids, to other molecules or surfaces. The PEG linker improves the stability and solubility of the conjugates, while the terminal carboxylic acid allows for the formation of stable covalent bonds.
Used in Material Science:
In material science, 2,2-DIMETHYL-4-OXO-3,8,11,14-TETRAOXA-5-AZAHEXADECAN-16-OIC ACID is used as a component in the development of new materials with specific properties. 2,2-DIMETHYL-4-OXO-3,8,11,14-TETRAOXA-5-AZAHEXADECAN-16-OIC ACID's ability to form stable amide bonds and its hydrophilic nature make it suitable for creating materials with tailored characteristics, such as self-healing properties or stimuli-responsive behavior.

Upstream product

• 6338-55-2 2-(2-(2-aminoethoxy)ethoxy)ethan-1-ol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 86520-52-7 2-[2-(2-azidoethoxy)ethoxy]ethanol 

Downstream Products

• 503071-54-3 {2-[2-(2-tert-butoxycarbonylamino-ethoxy)-ethoxy]-ethoxy}-acetic acid pentafluorophenyl ester 
• 916918-01-9 C₂₃H₃₅N₃O₉ 
• 2010159-56-3 (2S,4R)-1-[(2S)-2-(2-{2-[2-(2-aminoethoxy)ethoxy]ethoxy}-acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide 
• 916918-03-1 C₂₁H₂₅N₃O₉ 
• 916918-02-0 C₂₂H₃₃N₃O₉ 

Relevant articles and documents

Multiple arms polymerization target anticancer conjugate

Disclosed is a multi-arm targeting drug conjugate modified by a water-soluble polymer; the drug conjugate has the structural formula of (III). In formula (III), R is an organic core, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is a camptothecin-based drug, and q is any integer between 3 and 8. The drug conjugate may improve the poor water solubility, high toxicity and low bioavailability of camptothecin-based drugs.

Targeting multi-arm conjugate (by machine translation)

The present invention discloses a multi-arm, by the water-soluble polymer modified folic acid receptor targeted drug conjugates and salts thereof. The drug conjugate has the following structural formula: The invention is a multi-arm polymer modified targeting anticancer conjugate, wherein the water-soluble polymer may be modified to enhance the water solubility of the conjugate, thereby increasing the drug loading. In the invention of targeting molecules for folic acid, folic acid as a targeting molecule, folic acid receptor expressing abundant active targeting of tumor cells, play a better anti-tumor efficacy, increase target, and thus make the concentration of the conjugate in the targeted tissue more high. (by machine translation)

COMPOUNDS AND METHODS FOR OPTICAL SENSING OF ELECTRICAL ACTIVITY IN BIOLOGICAL SYSTEMS

Disclosed are tethered chromophore compositions comprising a membrane-spanning tether. The compounds can include covalently tethered fluorophore-quencher combinations useful for measuring action potentials and other fast electrical events in cells and tissues.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

EXENATIDE MODIFIER AND USE THEREOF

Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.

Zinc(II)cyclen-peptide conjugates interacting with the weak effector binding state of Ras

Zinc(II)cyclen-peptide hybrid compounds and bis-zinc(II)cyclen complexes are prepared as potential binders of the guanine nucleotide binding protein Ras, an important molecular switch in cellular signal transduction. The design of the compounds is based on the previous observation that zinc(II)cyclen complexes could serve as lead compounds for inhibitors of Ras-effector interaction and thus be able to interrupt Ras induced signal transduction. Zinc(II)cyclen selectively stabilizes conformational state 1 of active Ras, a conformational state with drastically decreased affinity to effector proteins like Raf-kinase. To achieve higher binding affinities of such Ras-Raf interaction inhibitors, zinc(II)cyclen conjugates with short peptides, derived from the sequence of the Ras-activator SOS, were prepared by solid phase synthesis protocols. Dinuclear bis-zinc(II)cyclen complexes were obtained from alkyne-azide cycloaddition reactions. NMR investigations of the prepared compounds revealed that the peptide conjugates do not lead to an increase in Ras binding affinity of the metal complex-peptide conjugates. The dinuclear zinc complexes lead to an immediate precipitation of the protein prohibiting spectroscopic investigations of their binding.